Main content

    Lung Cancer Clinical Trials

    CPMC Cancer Services Opens new window

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: PRIMAL STUDY: A Phase 1b/2, Randomized, Multicenter, Multinational Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Docetaxel (PDoc) Compared With Docetaxel (Doc) Alone in Subjects with Recurrent Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Decscription: This study is designed to assess the safety and tolerability of the combination of PEGPH20 with docetaxel (PDoc)
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, with histologically confirmed and documented previously treated Stage IIIB or IV NSCLC having failed no more than 1 previous platinum-containing chemotherapy regimen
    Status: Active and open to enrollment
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study HALO-107-201

    Title: A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
    Decscription: The purpose of this study is to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, with histologically or cytologically confirmed diagnosis of nonsquamous NSCLC that is Stage IIIB Stage IV, or recurrent after prior definitive intervention (radiation, surgery, or chemoradiation therapy, with or without adjuvant or neoadjuvant chemotherapy)
    Status: Active and open to enrollment
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study Incyte 266

    Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
    Description: This is a double-blind, randomized, placebo-controlled phase 3 non-inferiority study in subjects with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV Non-Small Cell Lung Cancer (NSCLC)
    Investigator (Santa Rosa): Peter Brett, MD
    Eligibility: Subjects, 18 y/o and older, with stage IV NSCLC (not recurrent or re-staged)
    Status: Active and open to enrollment
    Contact (Santa Rosa): Christina DeVisser, 707-576-4739, Email: DevissC@cpmcri.org about Study Amgen 20070782

    Title: Title: Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
    Decscription: Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 20 y/o and older, with histologically confirmed NSCLC with either: Metastatic disease (Stage IV) OR Stage IIIB disease not amenable to surgery or curative intent
    Status: Coming soon
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study Daiichi Lung

    Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
    Decscription: This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with stage IB-IIIA non-small cell lung cancer
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study A151216

    Title: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
    Decscription: This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who were previously registered to study A151216, with the result of lung cancer harboring an EGFR exon 19 deletion or L858R mutation
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study A081105

    Title: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
    Decscription: This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with histologically or cytologically documented small cell lung cancer (SCLC)
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study CALGB 30610

    Title: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
    Decscription: This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who have undergone complete surgical resection of their stage IB (>= 4 cm), II, or IIIA NSCLC per American Joint Committee on Cancer (AJCC) 7th edition and have had negative margins
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study ECOG-ACRIN E4512

    Title: Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
    Decscription: This randomized phase III trial is studying bevacizumab and pemetrexed disodium alone or in combination after induction therapy to see how well they work in treating patients with advanced non-squamous non-small cell lung cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with cytologically or histologically confirmed non-small cell lung cancer (NSCLC)
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study ECOG E5508

    Title: Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy +/- Cetuximab in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10)
    Decscription: This randomized phase II trial is studying chemotherapy and radiation therapy to see how well they work when given with or without panitumumab in treating patients with stage IIIA non-small cell lung cancer. (cetuximab closed as of 05/14/10)
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with histologically confirmed non-small cell lung cancer (NSCLC)
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study RTOG 0839

    Title: S1400 Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
    Decscription: This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study "Master Protocol"
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who have pathologically proven squamous cell non-small cell lung cancer (NSCLC) confirmed by tumor biopsy and/or fine-needle aspiration
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study SWOG S1400

    • updated March 2015

    Back to top